Evidence map›Paper›PMID 34840232›Full record

ArticleInternal medicine (Tokyo, Japan)2022

MPO-ANCA-positive Microscopic Polyangiitis Following COVID-19 Infection.

Soko Kawashima, Mitsumasa Kishimoto, Tomoya Hibino, Hearyoung Lee, Yuriko Sato, Yoshinori Komagata, Shinya Kaname

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. COVID-19 and Glomerular Diseases.Kidney international reports · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Soko KawashimaDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Mitsumasa KishimotoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Tomoya HibinoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Hearyoung LeeDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Yuriko SatoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Yoshinori KomagataDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Shinya KanameDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Kyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic disease that causes vasculitis in various organs. Although the cause of the onset is unknown, infection has been reported to be a causative factor. The subsequent cytokine storm triggered by the immune response against SARS-CoV-2 infection has been reported to lead to symptoms being more severe. We herein report our experience with the onset of AAV following COVID-19 infection. We also report the course of anti-SARS-CoV-2 serum antibody titers following induction therapy, which suggests that vaccination and education concerning standard precautions are necessary in patients who require immunosuppressive therapy, even after COVID-19 infection.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCOVID-19Microscopic PolyangiitisAntibodies, Antineutrophil CytoplasmicHumansPeroxidaseSARS-CoV-2Antibodies, Antineutrophil CytoplasmicPeroxidaseCOVID-19MPO-ANCArapidly progressive glomerulonephritisSARS-CoV-2vasculitis

Identifiers

PMID34840232
PMCPMC8907777
OpenAlexW3216843202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.